Cargando…
Therapeutic Potential of Butyrate for Treatment of Type 2 Diabetes
Metagenomics studies have shown that type 2 diabetes (T2D) is associated with an altered gut microbiota. Whereas different microbiota patterns have been observed in independent human cohorts, reduction of butyrate-producing bacteria has consistently been found in individuals with T2D, as well as in...
Autores principales: | Arora, Tulika, Tremaroli, Valentina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560891/ https://www.ncbi.nlm.nih.gov/pubmed/34737725 http://dx.doi.org/10.3389/fendo.2021.761834 |
Ejemplares similares
-
Sodium Butyrate Ameliorates Streptozotocin-Induced Type 1 Diabetes in Mice by Inhibiting the HMGB1 Expression
por: Guo, Yu, et al.
Publicado: (2018) -
Impact of Sodium Butyrate Treatment in LPS-Stimulated Peripheral Blood Mononuclear Cells of Poorly Controlled Type 2 DM
por: Wibowo, Heri, et al.
Publicado: (2021) -
Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes
por: Hou, Xintong, et al.
Publicado: (2022) -
Potential therapeutic role of pyroptosis mediated by the NLRP3 inflammasome in type 2 diabetes and its complications
por: Li, Xiang, et al.
Publicado: (2022) -
Butyrate and obesity: Current research status and future prospect
por: Peng, Ke, et al.
Publicado: (2023)